ARS Pharmaceuticals, Inc. SPRY Q2 2025 earnings
Reported August 13, 2025 · Before market open
Revenue estimate$27.7M
EPS estimate-$0.41
Next report
Aug 12, 2026 (in a month)Revenue estimate$31.3M
EPS estimate-$0.48
Financials
Q2 2025Valuation & ratios
Versus estimates
Revenue
Diluted EPS
Ask the moment ARS Pharmaceuticals, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did ARS Pharmaceuticals, Inc. report Q2 2025 earnings?
- ARS Pharmaceuticals, Inc. (SPRY) reported Q2 2025 earnings on August 13, 2025 before market open.
- What were ARS Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
- ARS Pharmaceuticals, Inc. reported revenue of $15.7M and diluted EPS of $-0.46 for Q2 2025.
- Did ARS Pharmaceuticals, Inc. beat estimates in Q2 2025?
- Revenue missed the consensus estimate of $27.7M by $12.0M. EPS missed the consensus estimate of $-0.41 by $0.05.
- How did ARS Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 3043.4% from $500.0K a year earlier and diluted EPS declined 253.8% from $-0.13.
- Where can I find ARS Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
- You can read the 10-Q periodic report (0000950170-25-107618) directly on SEC EDGAR. The filing index links above go to sec.gov.